About Servier

– Backgrounder –

Servier is France’s leading independent pharmaceutical company and the country’s second largest drug company. Servier is present in 140 countries worldwide. R&D at Servier spans a range of therapeutic fields, with the main areas of focus being cardiovascular disease, neuroscience, oncology, metabolic disorders, and rheumatology. In the field of cardiovascular disease in particular, Servier is one of the principal research organizations dedicated to the development of new medicines.

Cardiovascular commitment
Servier has a long-standing interest in the field of cardiovascular disease. Nearly two thirds (63%) of Servier’s global turnover from medicines is made up of drugs targeted at cardiovascular diseases.

Servier is unique among global pharmaceutical companies in that all the company’s cardiovascular products it has introduced have stemmed from its own research efforts.

Procoralan* (ivabradine) is the first and only specific and selective If current inhibitor of the sinus node. Procoralan was approved in 2005 by the European regulatory authorities (EMEA) for clinical use in selected patients with chronic stable angina. It is currently available in around 70 countries worldwide.

Servier’s cardiovascular portfolio also includes Coversyl® (perindopril), Servier’s leading product for high blood pressure, heart failure, and for the treatment of patients with stable coronary artery disease (CAD) to reduce the risk of coronary events, Vastarel MR® (trimetazidine) for stable angina and Preterax® (perindopril / indapamide) and Natrilix® SR (indapamide) for hypertension.

Servier and landmark clinical trials
Servier has been involved in several large-scale outcomes clinical trials for several years including the BEAUTIFUL (MorBidity-mortality EvAluA tion of the If Inhibitor ivabradine in patients with coronary disease and left ventricUl ar dysfunction) trial, which demonstrated the benefits of Procoralan (ivabradine) in reducing cardiovascular events in patients with coronary artery disease (CAD) receiving current preventative therapy. The results of this trial have major implications for the management of cardiovascular disease.
Other Servier trials include the **ADVANCE (Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation)** study. This is the world’s largest prospective mortality/morbidity trial in patients with type 2 diabetes to date. The study demonstrated the effects of blood pressure lowering with Preterax®-based therapy and intensive glucose-lowering with Diamicron MR-based therapy on the risk of complications in patients with type 2 diabetes.

The efficacy of perindopril alone and in combination has been investigated in a number of trials. The **PROGRESS (Perindopril prOtection aGainst REcurrent Stroke Study)** showed that perindopril 4 mg + indapamide 2.5 mg reduced the risk of stroke by 29% in patients with a history of cerebrovascular disease.

The **EUROPA** study (European trial on **Reduction Of** cardiac events with Perindopril in stable coronary Artery disease) showed that perindopril 8 mg is associated with a 20% reduction in the risk of cardiovascular death, myocardial infarction, and cardiac arrest compared with placebo in patients with coronary heart disease.

Other significant, independent, investigator-led trials include **ASCOT-BPLA** in hypertension (amlodipine + perindopril), **PREAMI** in postmyocardial infarction in elderly (perindopril) and **PEP-CHF** in diastolic heart failure (perindopril).

*Depending on the country, ivabradine is available as Procoralan®, Coralan®, Coraxan®, or Corlentor®

References
